Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to
 treat papillary thyroid carcinoma.
Investigators plan to identify patients with small papillary thyroid carcinoma and subject
 such patients to radiofrequency ablation (RFA) therapy.

 Following RFA procedure patients will be monitored to study the changes in primary tumor
 volume, development of lymph node involvement, development of distant metastasis and changes
 in serum thyroid hormone levels.

 Investigators will also assess the stability of these changes (need for repeat therapy) and
 the safety of the RFA procedure.
Inclusion Criteria:

 -  Are adults

 -  Nodule with Papillary thyroid carcinoma meeting the below criteria:

 -  Diagnosed by FNA cytology.

 -  Size < 1.5 cm

 -  Non-surgical therapy is considered acceptable by the treating physician

 -  Radiology evaluation deems the lesion amenable to RFA therapy with minimal risk
 of complication

 Exclusion Criteria:

 -  Clinical evidence for a multifocal papillary thyroid malignancy

 -  Clinical evidence for local or distant metastatic disease

 -  Pregnancy

 -  Vocal cord paralysis on contralateral side

 -  Coagulopathy or patients on anticoagulation therapy

 -  Patients with prior neck surgery or neck radiation

 -  Patients with neck anatomy that precludes easy access by RFA

 -  Patients with comorbidities deemed too high of a risk for general anesthesia

 -  Treatment with another investigational drug or intervention (within 6 weeks of planned
 RFA).

 -  Current drug or alcohol use or dependence that, in the opinion of the site
 investigator, would interfere with adherence to study requirements.